

Title (en)

AN ANTI-CD137 ANTIBODY AS AN AGENT IN THE TREATMENT OF CANCER AND GLYCOSYLATION VARIANTS THEREOF

Title (de)

ANTI-CD137-ANTIKÖRPER ALS MITTEL FÜR DIE BEHANDLUNG VON KREBS, UND GLYKOSYlierungSVarianten Davon

Title (fr)

ANTICORPS ANTI-CD137 EN TANT QU'AGENT DANS LE TRAITEMENT DE CANCERS ET VARIANTE DE GLYCOSYLATION DUDIT ANTICORPS

Publication

EP 1851244 A4 20090415 (EN)

Application

EP 05723079 A 20050215

Priority

US 2005004739 W 20050215

Abstract (en)

[origin: WO2006088447A1] The current invention relates to the development and methods of use of a recombinant agonistic antibody anti-human CD137, and glycosylation variants thereof. These antibodies act as an anti-cancer agents and/or immune modulators that are effective in shrinking solid tumors or other cancerous indications and preventing their recurrence. The types of cancer for which the contemplated antibody is effective in treating also include leukemia and lymphoma. In a preferred embodiment the recombinant antibodies of the current invention were produced in and purified from the milk of transgenic animals.

IPC 8 full level

C07K 16/00 (2006.01); **A61K 39/395** (2006.01); **C12P 21/00** (2006.01)

CPC (source: EP)

C07K 16/2878 (2013.01); **A61K 2039/507** (2013.01); **C07K 2317/12** (2013.01); **C07K 2317/74** (2013.01); **C07K 2317/75** (2013.01)

Citation (search report)

- [XY] US 2004025193 A1 20040205 - ECHELARD YANN [US], et al
- [Y] WO 03049755 A1 20030619 - MAYO FOUNDATION [US], et al
- [Y] WO 2004010947 A2 20040205 - BRISTOL MYERS SQUIBB CO [US], et al
- [XY] WO 0029445 A1 20000525 - LG CHEMICAL LTD [KR]
- [XY] WO 9816249 A1 19980423 - BRISTOL MYERS SQUIBB CO [US]
- [Y] POLLOCK D P ET AL: "Transgenic milk as a method for the production of recombinant antibodies", JOURNAL OF IMMUNOLOGICAL METHODS, ELSEVIER SCIENCE PUBLISHERS B.V.,AMSTERDAM, NL, vol. 231, no. 1-2, 10 December 1999 (1999-12-10), pages 147 - 157, XP004186081, ISSN: 0022-1759
- [Y] MEADE H M ET AL: "Expression of recombinant proteins in the milk of transgenic animals", GENE EXPRESSION SYSTEMS. USING NATURE FOR THE ART OF EXPRESSION, XX, XX, 1 January 1999 (1999-01-01), pages 399 - 427, XP009088286
- [X] WRIGHT A ET AL: "EFFECT OF ALTERED CH2-ASSOCIATED CARBOHYDRATE STRUCTURE ON THE FUNCTIONAL PROPERTIES AND IN VIVO FATE OF CHIMERIC MOUSE-HUMAN IMMUNOGLOBULIN G1", JOURNAL OF EXPERIMENTAL MEDICINE, ROCKEFELLER UNIVERSITY PRESS, JP, vol. 180, no. 3, 1 September 1994 (1994-09-01), pages 1087 - 1096, XP000676306, ISSN: 0022-1007
- [X] HORAN-HAND P ET AL: "COMPARATIVE BIOLOGICAL PROPERTIES OF A RECOMBINANT CHIMERIC ANTI-CARCINOMA MAB AND A RECOMBINANT AGLYCOSYLATED VARIANT", CANCER IMMUNOLOGY IMMUNOTHERAPY, vol. 35, no. 3, 1992, pages 165 - 174, XP001539281, ISSN: 0340-7004
- [A] SHIELDS ROBERT L ET AL: "Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fc gamma RIII and antibody-dependent cellular toxicity", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOCHEMICAL BIOLOGISTS, BIRMINGHAM,; US, vol. 277, no. 30, 26 July 2002 (2002-07-26), pages 26733 - 26740, XP002442140, ISSN: 0021-9258
- [A] OKAZAKI A ET AL: "Fucose Depletion from Human IgG1 Oligosaccharide Enhances Binding Enthalpy and Association Rate Between IgG1 and Fc gamma RIIIa", JOURNAL OF MOLECULAR BIOLOGY, LONDON, GB, vol. 336, no. 5, 5 March 2004 (2004-03-05), pages 1239 - 1249, XP004490178, ISSN: 0022-2836
- [A] HUMPHREYS D P ET AL: "THERAPEUTIC ANTIBODY PRODUCTION TECHNOLOGIES: MOLECULES, APPLICATIONS, EXPRESSION AND PURIFICATION", CURRENT OPINION IN DRUG DISCOVERY AND DEVELOPMENT, CURRENT DRUGS, LONDON, GB, vol. 4, no. 2, 1 March 2001 (2001-03-01), pages 172 - 185, XP008016086, ISSN: 1367-6733
- [T] ZHOU Q ET AL: "Effect of genetic background on glycosylation heterogeneity in human antithrombin produced in the mammary gland of transgenic goats", JOURNAL OF BIOTECHNOLOGY, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 117, no. 1, 20 April 2005 (2005-04-20), pages 57 - 72, XP004836787, ISSN: 0168-1656
- See references of WO 2006088447A1

Citation (examination)

- SHIELDS R L ET AL: "High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R", JOURNAL OF BIOLOGICAL CHEMISTRY, THE AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, INC., BALTIMORE, MD, US, vol. 276, no. 9, 2 March 2001 (2001-03-02), pages 6591 - 6604, XP002495886, ISSN: 0021-9258, [retrieved on 20001128], DOI: 10.1074/JBC.M009483200
- W. LIN ET AL: "Fc-dependent expression of CD137 on human NK cells: insights into "agonistic" effects of anti-CD137 monoclonal antibodies", BLOOD, vol. 112, no. 3, 1 August 2008 (2008-08-01), pages 699 - 707, XP055037053, ISSN: 0006-4971, DOI: 10.1182/blood-2007-11-122465

Designated contracting state (EPC)

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

DOCDB simple family (publication)

WO 2006088447 A1 20060824; EP 1851244 A1 20071107; EP 1851244 A4 20090415; EP 2399935 A2 20111228; EP 2399935 A3 20120222

DOCDB simple family (application)

US 2005004739 W 20050215; EP 05723079 A 20050215; EP 11173253 A 20050215